12 unknown. 12 Phase 2, 4 Phase 1, 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 12 | Unknown 12 |
| Phase 1 | 4 | Unknown 4 |
| Phase 3 | 1 | Unknown 1 |
Follow Primary Myelofibrosis: new trials by email Literature Review of Primary Myelofibrosis trials Research Report on Primary Myelofibrosis
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Ropeginterferon Alfa 2b for Early MyelofibrosisDIPSS Low/Intermediate-1 Risk Myelofibrosis Ropeginterferon Alfa-2B Prefilled Syringe [Besremi] - Pre-fibrotic Myelofibrosis | Phase 2 | Unknown | National Taiwan University Hospital | 50 | 2023-02-08 | 2023-02-16 |
| Bomedemstat (IMG-7289) Plus Ruxolitinib for Myelofibrosis Bomedemstat - Myelofibrosis | Phase 2 | Unknown | The University of Hong Kong | 40 | 2022-12-01 | 2023-05-23 |
| Ropeginterferon Alfa 2b for Early Myelofibrosis Ropeginterferon alfa-2b - Primary Myelofibrosis, Prefibrotic Stage, Myelofibrosis | Phase 2 | Unknown | The University of Hong Kong | 50 | 2021-09-01 | 2022-10-06 |
| Study of KRT-232 or TL-895 in Janus Associated Kinase Inhibitor Treatment-Naïve Myelofibrosis KRT-232, TL-895 - Primary Myelofibrosis (PMF), Post-Polycythemia Vera Myelofibrosis (Post-PV-MF) | Phase 2 | Unknown | Kartos Therapeutics, Inc. | 52 | 2021-04-13 | 2022-05-09 |
| Haplo-identical Transplantation in Patients With Myelofibrosis - A Phase 2 Prospective Multicentric Prospective Study Allogenic transplantation transplantation - Myelofibrosis | Phase 2 | Unknown | Assistance Publique - Hôpitaux de Paris | 28 | 2021-01-30 | 2021-01-28 |
| An Open-Label, Multicenter, Phase 1b/2 Study of the Safety and Efficacy of KRT-232 Combined With Ruxolitinib in Patients With Primary Myelofibrosis (PMF), Post-Polycythemia Vera MF (Post-PV-MF), Or Post-Essential Thrombocythemia MF (Post ET-MF) Who Have a Suboptimal Response to Ruxolitinib KRT-232, Ruxolitinib - Myelofibrosis | Phase 1 / Phase 2 | Unknown | Kartos Therapeutics, Inc. | 36 | 2021-01-28 | 2022-05-09 |
| KRT-232 in Combination With TL-895 for the Treatment of R/R MF and KRT-232 for the Treatment of JAKi Intolerant MF KRT-232, TL-895 - Myelofibrosis, Post-PV MF | Phase 1 / Phase 2 | Unknown | Kartos Therapeutics, Inc. | 116 | 2020-11-17 | 2022-05-09 |
| Study of TL-895 in Subjects With Myelofibrosis or Indolent Systemic Mastocytosis TL-895, Placebo - Myelofibrosis, Indolent Systemic Mastocytosis | Phase 2 | Unknown | Telios Pharma, Inc. | 121 | 2020-10-22 | 2024-05-10 |
| KRT-232 Versus Best Available Therapy for the Treatment of Subjects With Myelofibrosis Who Are Relapsed or Refractory to JAK Inhibitor Treatment KRT-232, Best Available Therapy (BAT) - Primary Myelofibrosis (PMF), Post-Polycythemia Vera MF (Post-PV-MF) | Phase 2 / Phase 3 | Unknown | Kartos Therapeutics, Inc. | 385 | 2019-01-15 | 2023-04-28 |
| LBH589 (Panobinostat) for the Treatment of Myelofibrosis LBH589 - Primary Myelofibrosis, Polycythemia Vera, Post-Polycythemic Myelofibrosis Phase | Phase 1 / Phase 2 | Unknown | Ronald Hoffman | 22 | 2009-09-01 | 2015-03-06 |
| CEP-701 (Lestaurtinib) in Myelofibrosis CEP-701 (Lestaurtinib) - Myelofibrosis, Essential Thrombocythemia | Phase 1 / Phase 2 | Unknown | Ronald Hoffman | 60 | 2008-04-01 | 2014-11-26 |
| Light-Emitting Diode Therapy in Preventing Mucositis in Children Receiving Chemotherapy With or Without Radiation Therapy Before Bone Marrow Transplantation management of therapy complications, pain therapy - Chronic Myeloproliferative Disorders, Kidney Cancer | Phase 2 | Unknown | Medical College of Wisconsin | 80 | 2002-01-01 | 2013-09-20 |
Polycythemia Vera (2) · Blast Crisis (1) · Burkitt Lymphoma (1) · Dendritic Cell Sarcoma, Interdigitating (1) · Kidney Neoplasms (1) · Leukemia (1) · Leukemia, Hairy Cell (1) · Leukemia, Lymphocytic, Chronic, B-Cell (1) · Leukemia, Myeloid, Accelerated Phase (1) · Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative (1) · Leukemia, Myeloid, Chronic-Phase (1) · Lymphoma (1) · Mastocytosis, Systemic (1) · Multiple Myeloma (1)
Bone Marrow Diseases (12) · Hematologic Diseases (12) · Hemic and Lymphatic Diseases (12) · Myeloproliferative Disorders (11) · Neoplasms (4) · Neoplasms by Site (3) · Bone Marrow Neoplasms (2) · Hematologic Neoplasms (2) · Hemorrhagic Disorders (2) · Immune System Diseases (2) · Neoplasms by Histologic Type (2) · Neoplasms, Connective and Soft Tissue (2) · Adnexal Diseases (1) · Blood Coagulation Disorders (1) · Blood Platelet Disorders (1)
navtemadlin; 2-((3R,5R,6S)-5-(3-chlorophenyl)-6-(4-chlorophenyl)-1-((S)-1-(isopropylsulfonyl)-3-methylbutan-2-yl)-3-methyl-2-oxopiperidin-3-yl)acetic acid (4) · Analgesia (1) · Panobinostat (1) · bomedemstat (1) · lestaurtinib (1) · ruxolitinib (1)
Kartos Therapeutics, Inc. (4) · Ronald Hoffman (2) · The University of Hong Kong (2) · Assistance Publique - Hôpitaux de Paris (1) · Medical College of Wisconsin (1) · National Taiwan University Hospital (1) · Telios Pharma, Inc. (1)
United States (8) · Bulgaria (5) · Poland (5) · France (4) · Germany (4) · Italy (4) · Spain (4) · Australia (3) · Hong Kong (3) · Hungary (3) · Taiwan (3) · Brazil (2) · Israel (2) · Mexico (2) · Russia (2)
Ronald Hoffman, MD (2) · Harinder Gill, MD (1) · Harry T. Whelan, MD (1)
PMID 25563429, PMID 41758981, PMID 41875235
P01CA108671 (1)